Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The companyâs lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS). Source
No articles found.
MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedica...
MorphoSys (FSE & NASDAQ: MOR) is a clinical-sta...
Headquartered in Waltham, Massachusetts, we develop and deliver innovative medicin...
Headquartered in Waltham, Massachusetts, we dev...
Voyager Therapeutics is developing life-changing gene therapies for fatal and debi...
Voyager Therapeutics is developing life-changin...
Our strategy is to be known as âthe prostate cancer companyâ. We aspire to be ...
Our strategy is to be known as âthe prostate ...
Neoleukin is a biopharmaceutical company creating next generation immunotherapies ...
Neoleukin is a biopharmaceutical company creati...
Trovagene is a clinical-stage, oncology therapeutics company, taking a precision m...
Trovagene is a clinical-stage, oncology therape...
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing th...
Cyclerion Therapeutics is a clinical-stage biop...
Join the National Investor Network and get the latest information with your interests in mind.